EN PL
ORIGINAL PAPER
Diagnosis of polymyalgia rheumatica in primary health care: favoring and confounding factors – a cohort study
 
More details
Hide details
 
Submission date: 2017-12-29
 
 
Final revision date: 2018-03-19
 
 
Acceptance date: 2018-05-08
 
 
Online publication date: 2018-06-30
 
 
Publication date: 2018-06-30
 
 
Reumatologia 2018;56(3):131-139
 
KEYWORDS
TOPICS
ABSTRACT
Objectives:
To evaluate in a primary care setting the favoring and confounding factors for the diagnosis of polymyalgia rheumatica (PMR).

Material and methods:
Among 303 patients consecutively referred by their general practitioners (GPs) to our rheumatologic outpatient clinic, we identified three groups: group A – patients with confirmed diagnosis of PMR, group B – patients with unconfirmed diagnosis, group C – patients with unrecognized PMR. All the diagnostic confounding and favoring factors were discussed with GPs using an e-mail questionnaire. Participation in rheumatology training courses represented the final question. The collected data were statistically assessed in a blind way. In Fisher’s exact test and ANOVA test, a p-value was significant if < 0.05. The study was carried out in compliance with the Helsinki Declaration and approved by the Ethics Committee of Mariano Lauro Hospital. Every patient signed an informed consent form at the time of the first visit.

Results:
All patients were Caucasian; 24.1% were male; mean age was 72.3 ±8.6 years (min. – 51, max. – 94). There were 41 patients in group A, 93 in group B and 169 in group C. The percentage of misdiagnoses was very high (87.1%): among 134 patients diagnosed with PMR by their GPs (group A + group B) confirmation was made in 41, and in 169 unrecognized PMR was found. Participation in training courses was very significant compared to the diagnostic accuracy (p < 0.0001 in χ2 test) and to the diagnosis timing (24.3 days ±12.5 vs. 42.9 ±15.5 with p-value < 0.05 in the ANOVA test). When the percentages were assessed according to participation, an inadequate evaluation of some clinical manifestations favored over-diagnosis among the trained Gps.

Conclusions:
The level of diagnostic accuracy for PMR must be improved in primary care. Participation in rheumatology training courses can be an important step.

 
REFERENCES (31)
1.
González-Gay MA, Matteson EL, Castan"eda S. Polymyalgia rheumatica. Lancet 2017; 390: 1700-1712.
 
2.
Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia Rheumatica and Giant Cell Arteritis. JAMA 2016; 315: 2442-2458.
 
3.
Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing and monitoring in general practice. Br J Gen Pract 2013; 63: e361-366.
 
4.
Mathew R, Rashid A. Polymyalgia rheumatica in primary care: managing diagnostic uncertainty. BMJ 2015; 351: h5199.
 
5.
Manzo C, Balduccelli M, Cappiello F, et al. Prevalence and incidence of polymyalgia rheumatica in Massa Lubrense, Italy. Trends Med 2009; 9: 85-89.
 
6.
Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence of synovitis. Semin Arthritis Rheum 1984; 13: 322-328.
 
7.
Ceccato F, Uńa C, Regidor M, et al. Conditions mimicking polymyalgia rheumatica. Reumatol Clin 2011; 7: 156-160.
 
8.
Manzo C, Camellino D. La polimialgia reumatica: difficoltà diagnostiche e terapeutiche per una malattia apparentemente “banale”. Recenti Prog Med 2017; 108: 221-231.
 
9.
Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992; 19: 270-272.
 
10.
Olivo D, D’Amore M, Mattace-Raso F, et al. Clinical and laboratory features at onset of polymyalgia rheumatica (PMR) and elderly onset of rheumatoid arthritis in PMR-like presentation: a comparison of two groups of patients. Arch Gerontol Geriatr 1996; 22 suppl 1: 527-533.
 
11.
Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology 2009; 48: 123-127.
 
12.
Caporali R, Montecucco C, Epis O, et al. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis 2001; 60: 1021-1024.
 
13.
Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-439.
 
14.
Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168-170.
 
15.
Proven A, Gabriel SE, Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26: 1333-1337.
 
16.
Dalkılıç E, Tufan AN, Hafızoğlu E, et al. The process from symptom onset to rheumatology clinic in polymyalgia rheumatica. Rheumatol Int 2014; 34: 1589-1592.
 
17.
Manzo C, Natale M. Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set. Open Access Rheumatol 2016; 8: 93-95.
 
18.
Manzo C, Stisi S. La sindrome RS3PE: tre cose utili da ricordare per il geriatra. GerExtraosp 2016; XI: 23-25.
 
19.
Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica: Report of nineteen cases. Arthritis Rheum 1996; 39: 73-80.
 
20.
Manzo C. The paraneoplastic meaning of R3SPE (remitting seronegative simmetrical synovitis with pitting edema) syndrome. J Med Oncl Ther 2016; 1: 72-75.
 
21.
Manzo C, Natale M. Polymyalgia Rheumatica in Association with Remitting Seronegative Sinovitis with Pitting Edema: a Neoplastic Warning. Can Geriatr J 2017; 20: 94-96.
 
22.
Pego-Reigosa JM, Rodriguez-Rodriguez M, Hurtado-Hernandez Z, et al. Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum 2005; 53: 931-938.
 
23.
Dieppe PA, Alexander GJ, Jones HE, et al. Pyrophosphate arthropathy: a clinical and radiological study of 105 cases. Ann Rheum Dis 1982; 41: 371-376.
 
24.
Olivieri I, Garcia-Porrua C, Padula A, et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol Int 2007; 27: 927-933.
 
25.
Aydeniz A, Altındağ O, Oğüt E, et al. Late onset spondyloarthropathy mimicking polymyalgia rheumatica. Rheumatol Int 2012; 32: 1357-1358.
 
26.
Kouassi Djaha J-M, Jenvrin C, Dupont M-P, et al. Late onset spondyloarthropathy misdiagnosed as polymyalgia rheumatica. Rev Med Interne 2013; 34: 667-670.
 
27.
Yates M, Graham K, Watts RA, MacGregor AJ. The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskelet Disord 2016; 17: 285.
 
28.
Barraclough K, Liddell WG, du Toit J, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract 2008; 25: 328-333.
 
29.
Quick V, Kirwan JR. Our approach to the diagnosis and treatment of polymyalgia rheumatica and giant cell (temporal) arteritis. J R Coll Physicians Edinb 2012; 42: 341-349.
 
30.
Rooney PJ, Rooney J, Balint G, et al. Polymyalgia rheumatica: 125 years of epidemiological progress? Scottish Med J 2015; 60: 50-57.
 
31.
Muller S, Hider S, Helliwell T, et al. The epidemiology of polymyalgia rheumatica in primary care: a research protocol. BMC Musculoskelet Disord 2012; 13: 102.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top